Phase II trial of eribulin in patients who do not achieve pathologic complete response (pCR) following neoadjuvant chemotherapy. [electronic resource]
Producer: 20201210Description: 647-655 p. digitalISSN:- 1573-7217
- Adult
- Aged
- Anthracyclines -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Biomarkers, Tumor -- metabolism
- Breast Neoplasms -- drug therapy
- Bridged-Ring Compounds -- administration & dosage
- Chemotherapy, Adjuvant -- mortality
- Cohort Studies
- Drug Resistance, Neoplasm -- drug effects
- Female
- Follow-Up Studies
- Furans -- administration & dosage
- Humans
- Ketones -- administration & dosage
- Middle Aged
- Neoadjuvant Therapy -- mortality
- Non-Randomized Controlled Trials as Topic
- Prognosis
- Receptor, ErbB-2 -- metabolism
- Receptors, Estrogen -- metabolism
- Receptors, Progesterone -- metabolism
- Survival Rate
- Taxoids -- administration & dosage
- Trastuzumab -- administration & dosage
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article
There are no comments on this title.
Log in to your account to post a comment.